Abstract | INTRODUCTION: METHODS: We examined Romo1, ROS, and vascular endothelial growth factor ( VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection ( n=30) in accordance with clinical parameters including levels of Romo1 expression. RESULTS: Romo1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romo1 compared with high Romo1. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman's correlation analyses demonstrated significant positive correlations of Romo1 expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. CONCLUSION:
|
Authors | Hong Jun Kim, Min Jee Jo, Bo Ram Kim, Jung Lim Kim, Yoon A Jeong, Yoo Jin Na, Seong Hye Park, Suk-Young Lee, Dae-Hee Lee, Baek-Hui Kim, Young Do Yoo, Sang Cheul Oh |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 11
Pg. 4233-4246
( 2018)
ISSN: 1178-6930 [Print] New Zealand |
PMID | 30087567
(Publication Type: Journal Article)
|